Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.
about
Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical reviewCanadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity.A review of venous thromboembolism prophylaxis for hospitalized medical patients.Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients.Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations.The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety.Clinical Experience With Pharmacological Venous Thromboembolism Prophylaxis in the Underweight and Critically Ill.Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients.Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.Use of Enoxaparin in Obese Adolescents During Bariatric Surgery--a Pilot Study.Ineffective Treatment of Low-Molecular-Weight Heparin in Obese Subject with Traumatic Fractures of the Leg.Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications.Adjusted-Dose Enoxaparin for VTE Prevention in the Morbidly Obese.Saddle pulmonary embolus resulting in cardiovascular collapse requiring extracorporeal membrane oxygenation in a postoperative patient with endometrial cancer.
P2860
Q26992262-2B5B79A1-DCE6-42F0-820A-345995E482B9Q33422297-3A530DE6-6720-47B8-AAC2-3AFC53B52819Q34612869-6957CD86-D30E-4CF9-9FCB-000EA8EDC79DQ38129188-50E95EF3-DF24-41C7-B94D-5795266FB294Q38168477-66E3C2C6-8C60-4A59-8E68-E8F2A31831E3Q38485825-35F33149-136B-4D6C-8A36-EAD3955C8C4FQ38633482-E86FDA6F-937C-4574-A799-991369482CAFQ40670636-15E76C61-1922-4C08-B957-84C0EEF69694Q41231279-4AA4A1BA-52EC-4D11-BF63-33774C0B157DQ43426032-108AC09E-A217-4ECA-A973-20700CBF9752Q46105580-44D002CB-3CEA-4476-BFD2-0B3AACB98B46Q46618514-DD15CC86-4FAE-4F01-B77D-AAEAF2F44F25Q46698972-81AEB584-8855-42D5-8CB8-775BDB1AB426Q53101380-3F94EFD5-E451-4D2A-A24E-D42A7657B516Q55079673-8E1545CA-46C7-4802-983C-4144914E83CCQ55235456-E3B3D1C6-949F-4FBA-9C69-992B3038629DQ55409598-8C816B9A-C072-4587-8A24-C8969C303746
P2860
Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prospective comparison of thre ...... patients with extreme obesity.
@ast
Prospective comparison of thre ...... patients with extreme obesity.
@en
type
label
Prospective comparison of thre ...... patients with extreme obesity.
@ast
Prospective comparison of thre ...... patients with extreme obesity.
@en
prefLabel
Prospective comparison of thre ...... patients with extreme obesity.
@ast
Prospective comparison of thre ...... patients with extreme obesity.
@en
P2093
P2860
P356
P1476
Prospective comparison of thre ...... patients with extreme obesity.
@en
P2093
Andrew Freeman
Matthew T Rondina
Robert C Pendleton
Tuesdy Horner
P2860
P304
P356
10.1002/AJH.23228
P577
2012-05-06T00:00:00Z